OmniAb, Inc. (OABI) News
Follow OmniAb, Inc. (OABI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
OABI Reports Fiscal Q3 Net Loss
OABI reported a fiscal third-quarter net loss attributable to shareholders, up 42.11% year over year, and negative basic earnings per share.
EQUITY | Nov 02, 2026, 04:13 AM UTC
M
OmniAb Q3'26 Earnings Preview: EPS Estimate at (0.13) USD
OmniAb is scheduled to report Q3'26 results on October 30 after the market closes. Revenue is estimated at 3.49 million USD and EPS at (0.13) USD.
EQUITY | Oct 29, 2026, 11:01 AM UTC
M
OmniAb Q3 Revenue Estimate Ahead of Results
OmniAb is scheduled to report Q3 results on October 30 after market close. Revenue and EPS estimates were provided.
EQUITY | Oct 23, 2026, 11:01 AM UTC
L
OABI - OmniAb to Participate in Upcoming Investor Conferences
OABI - OmniAb to Participate in Upcoming Investor Conferences
EQUITY | Aug 26, 2026, 12:08 PM UTC
L
OmniAb to Participate in Upcoming Investor Conferences
OmniAb plans to participate in upcoming investor conferences, according to TradingView News.
EQUITY | Aug 26, 2026, 12:00 PM UTC
L
NY Empire State Manufacturing Index Rises to 20.6 in August
The New York Fed's Empire State Manufacturing Index surged to 20.6 in August from 15.6 in the prior month, topping market estimates of 11.
EARNINGS | Aug 17, 2026, 04:04 PM UTC
H
OmniAb lifts FY26 cash guidance; signs Eli Lilly ion-channel deal
OmniAb shares rise after the company revised its FY26 Cash and Cash Equivalent guidance above prior expectations and announced a global collaboration and license agreement with Eli Lilly for a new ion channel program.
EQUITY | Aug 17, 2026, 12:49 PM UTC
L
OABI raises 2026 cash guidance to $49M-$53M
OABI raised its 2026 cash guidance to expect year-end cash and equivalents of $49M-$53M, up from its prior $37M-$41M outlook, citing recent licensing activity.
EQUITY | Aug 17, 2026, 10:08 AM UTC
L
OmniAb raises 2026 financial guidance
OmniAb raises 2026 financial guidance; no further numbers or catalyst were supplied in the raw item.
EQUITY | Aug 17, 2026, 10:06 AM UTC
H
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Friday. Shares of Natera Inc (NASDAQ: NTRA ) rose sharply after the company reported better-than-expected quarterly financial results and raised its
EARNINGS | Aug 07, 2026, 07:35 PM UTC
L
OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est
OmniAb (NASDAQ: OABI ) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 million-$36.000 million vs $30.807 million estimate.
EARNINGS | Aug 06, 2026, 08:24 PM UTC
L
VRXI OABI veraxa Biotech announces advancement of novel bispecific antibody drug conjugate program vxa-222 from Joint Discovery collaboratio
VRXI OABI veraxa Biotech announces advancement of novel bispecific antibody drug conjugate program vxa-222 from Joint Discovery collaboration with Omniab
EQUITY | Jul 27, 2026, 11:23 AM UTC